Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Stopped early · Phase 1

Conditions studied: Healthy

In brief

A Phase 1, relative bioavailability study of BMS-931699 from prefilled syringe compared to drug in vial

Key facts

Study ID: NCT03058822
Run by: Bristol-Myers Squibb
People needed: 5
Starts: 2017-01-25
Expected to finish: 2017-03-30
Last updated by the study team: 2017-12-20

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Healthy participants as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms, and clinical laboratory determinations
All participants must have hemoglobin, hematocrit, and platelets within normal limits at screening
All participants must have activated partial thromboplastin time, prothrombin time, and international normalized ratio within normal limits at screening

You may not qualify if…

Any current or past history or risk for tuberculosis:
Active tuberculosis requiring treatment within the previous 3 years. All participants will be required to have a QuantiFERON tuberculosis Gold or T-SPOT tuberculosis test performed at screening. Also excluded are participants with evidence of a past tuberculosis infection without documented adequate therapy. Participants with a positive QuantiFERON tuberculosis Gold or T-SPOT tuberculosis test at screening will not be eligible for the study. A QuantiFERON tuberculosis Gold or T-SPOT tuberculosis test performed within 4 weeks of dosing on Day 1 is acceptable as long as there is documentation of a negative result.
Current clinical, radiographic, or laboratory evidence of active tuberculosis
A history of herpes zoster

Where it is running

Qps-Mra, Llc — South Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.